Effects on Hedonic Feeding, Energy Expenditure and Balance of the Non-opioid Peptide DYN-A2-17. (10th February 2018)

• Record Type: Journal Article
• Authors: Alvarez, B.; Barrientos, T.; Gac, L.; Teske, J.A.; Perez-Leighton, C.E.
• Is Part Of: Neuroscience. Volume 371(2018)
• Page Start: 337
• Page End: 345
• Publication Date: 2018-02-10
• Subjects: aCSF Artificial cerebrospinal fluid -- ACTH Adrenocorticotropic hormone -- CRF Corticotrophin-releasing factor -- DYN Dynorphin -- PVN Paraventricular hypothalamic nucleus -- SPA Spontaneous physical activity; dynorphin -- orexin -- exercise -- food intake -- energy expenditure -- hedonic food intake; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2017.11.044
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: DYN-A2-17 is a non-opioid dynorphin (DYN) peptide. Injection of DYN-A2-17 into PVN promotes spontaneous physical activity, exercise and energy expenditure. Repeated DYN-A2-17 injections into PVN increases short-term food intake without effects on cumulative food intake or body weight. The effects of DYN-A2-17 in PVN on food intake are blocked by pre-treatment with a CRF receptor antagonist. In PVN, DYN-A2-17 regulates hedonic food intake and choice differently from opioid DYN and orexin-A peptides. Abstract: The dynorphin (DYN) peptide family includes opioid and non-opioid peptides, yet the physiological role of the non-opioid DYN peptides remains poorly understood. Recent evidence shows that administering the non-opioid peptide DYN-A2-17 into the paraventricular hypothalamic nucleus (PVN) simultaneously increased short-term intake of standard rodent chow and spontaneous physical activity (SPA). The present studies aimed to expand upon the mechanisms and role of DYN-A2-17 on food intake and energy expenditure. Injection of DYN-A2-17 in PVN increased SPA, energy expenditure and wheel running in the absence of food. Repeated DYN-A2-17 injection in PVN increased short-term chow intake, but this effect habituated over time and failed to alter cumulative food intake, body weight or adiposity. Pre-treatment with a CRF receptor antagonist into PVN blocked the effects of DYN-A2-17 on food intake while injection of DYN-A2-17 in PVN increased plasma ACTH. Finally, as DYN peptides are co-released with orexin peptides, we compared the effects of DYN-A2-17 to orexin-A and the opioid peptide DYN-A1-13 on food choice and intake in PVN when palatable snacks and chow were available. DYN-A1-13 selectively increased intake of palatable snacks. DYN-A2-17 and orexin-A decreased palatable snack intake while orexin-A also increased chow intake. These findings demonstrate that the non-opioid peptide DYN-A2-17 acutely regulates physical activity, energy expenditure and food intake without long-term effects on energy balance. These data also propose different roles of opioid, non-opioid DYN and orexin peptides on food choice and intake when palatable and non-palatable food options are available.